Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions

DOI Web Site Web Site Web Site Web Site 被引用文献7件
  • Arne Gessner
    1Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany
  • Jörg König
    1Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany
  • Martin F. Fromm
    1Institute of Experimental and Clinical Pharmacology and Toxicology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg Erlangen Germany

抄録

<jats:p>Drug transporters play an essential role in disposition and effects of multiple drugs. Plasma concentrations of the victim drug can be modified by drug–drug interactions occurring in enterocytes (e.g., P‐glycoprotein), hepatocytes (e.g., organic anion‐transporting polypeptide 1B1 (OATP1B1)), and/or renal proximal tubular cells (e.g., organic cation transporter 2 (OCT2)/multidrug and toxin extrusion 1 and 2‐K (MATE1/MATE2‐K)). In addition, transporter‐mediated drug–drug interactions can cause altered local tissue concentrations and possibly altered effects/toxicity (e.g., in liver and kidneys). During drug development, there is now an intensive <jats:italic>in vitro</jats:italic> screening of new molecular entities as transporter substrates and inhibitors, followed if necessary by drug–drug interaction studies in healthy volunteers. Nevertheless, there are still unresolved issues, which will also be discussed in this review article (e.g., the clinical significance of transporter‐mediated drug–drug interactions of particular relevance to the elderly who are prescribed multiple drugs, with additional impaired liver or kidney function, and the extent to which medication safety in real life could be improved by a reduction of those interactions).</jats:p>

収録刊行物

被引用文献 (7)*注記

もっと見る

問題の指摘

ページトップへ